Achieve Life Sciences Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Achieve Life Sciences Inc 's ROA in the second quarter of 2026?
Achieve Life Sciences Inc recorded a cumulative net loss of $-114 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -91.07%.

However, within the Healthcare sector 805 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4302, from total ROA ranking in the first quarter of 2026 at 5018.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	534.48 %	21.01 %	8.17 %	110.02 %	-9.04 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-114	-52	-55	-52	-50
Return On Assets (TTM)	-91.07 %	-111.88 %	-121.36 %	-118.32 %	-134.71 %
ACHV's Total Ranking	# 4302	# 5018	# 4437	# 4510	# 4534
Total Assets (TTM) in million	374	33	42	52	59
Seq. Total Assets Change	1029.53 %	-20.78 %	-19.7 %	-11.7 %	115.42 %
Seq. Net Income Change	-	-	-	-	-

ACHV's 5 Years Annual ROA >> Back to ACHV Management Effectiveness >> Compare ACHV ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 14
Sector	# 806
Overall	# 4349

Return On Assets Statistics
High	Average	Low
12.81 %	-70.33 %	-161.39 %
(Dec 31 2012)		(Mar 31 2023)

News about Achieve Life Sciences Inc Return on Assets ROA

Achieve Life Sciences Strengthens Leadership and Progresses Toward Smoking Cessation Breakthrough with Cytisinicline

In a dynamic move poised to bolster its commercial strategy, Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company renowned for its innovative approach to nicotine dependence treatment, has announced the promotion of Ms. Jaime Xinos to the role of Chief Commercial Officer, effective immediately. This strategic decision comes against the backdrop of significant advancements in the company’s clinical endeavors, further solidifying its commitment to the global fight against smoking-related health issues.Achieve Life Sciences is currently gaining momentum with its lead therapeutic candidate, cytisinicline, which has garnered attention as a promising treatment for smoking cessation. On October 10, 2024, the company reported the successful completion of enrollment in the ORCA-OL trial—a pivotal study meticulously designed to assess the safety and effectiveness of cytisine as a smoking cessation aid. The trial s comprehensive methodology reflects Achieve s dedication to providing substantial clinical evidence, a crucial component as public health authorities increasingly emphasize the need for innovative interventions to curb tobacco use.

Achieve Life Sciences Finds Recognition in U.S. Russell Indexes, Signaling Potential Growth in Smoking Cessation Market

Seattle and Vancouver, British Columbia - Achieve Life Sciences, Inc. (Nasdaq: ACHV), a renowned late-stage pharmaceutical firm dedicated to the worldwide development and commercialization of cytisinicline for smoking cessation and nicotine dependence, proudly announced its recent inclusion in the esteemed U.S. Russell 3000 and Russell Microcap Indexes. Effective immediately, from the opening of the U.S. equity markets on Monday, July 1, 2024, this significant accomplishment solidifies the company s growing stature in the healthcare sector.
The addition to the U.S. Russell indexes marks a major milestone for Achieve Life Sciences, recognizing the company s exceptional progress and potential for market expansion. By joining these prestigious indexes, Achieve Life Sciences not only gains access to increased visibility but also showcases its strong position in the competitive landscape of smoking cessation treatments.
This latest recognition underpins the significant advancements made by Achieve Life Sciences in the field of smoking cessation. The company s commitment to developing and commercializing cytisinicline as an effective solution for smoking cessation and nicotine dependence has garnered widespread attention within the industry. With smoking being a leading cause of preventable deaths worldwide, Achieve Life Sciences focus on providing innovative therapies highlights their dedication to improving public health outcomes.

Financial Statements
Achieve Life Sciences Inc 's Assets	$ 374 million	ACHV's Balance sheet
Achieve Life Sciences Inc 's Income	$ -75 million	Quarterly ACHV's Income Statement
ACHV's Income by Division		See ACHV's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	8.17 %	99.44 %	-35.37 %	-36.92 %	17.91 %
Total Assets in million	42	39	19	30	48
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-55	-40	-30	-42	-33
Annual Return On Assets	-130.77 %	-103.09 %	-153.92 %	-141.3 %	-69.77 %

ACHV's 5 Years Annual ROA >> Back to ACHV Management Effectiveness >> Compare ACHV ROA to its Competitors

More Return On Assets Ratios
ACHV's' Return on Assets at Yahoo Finance
In Vitro & In Vivo Diagnostic Substances Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ACHV's Roa Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ACHV's Competitors
Subscribers only: Roa for Achieve Life Sciences Inc 's Suppliers
Subscribers only: Return On Assets for ACHV's Customers

You may also want to know
ACHV's Roi	ACHV's Inventory Turnover Ratio	ACHV's Growth Rates	ACHV's Dividend Comparisons
	ACHV's Profitability Ratios	ACHV's Asset Turnover Ratio	ACHV's Dividend Growth
ACHV's Roe	ACHV's Valuation Ratios	ACHV's Financial Strength Ratios	ACHV's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:01:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.